Search results for 'Wockhardt Ltd'

'Whatever I have is because of India'

'15, 17 years back we were not even in existence in the US. Today nearly 1/3 of prescriptions written comes from India.' 'India is showing that in a very competitive environment -- like the US and Europe -- our industry is doing very well.'

'You can't succeed without taking risk'

'There are different kinds of risk.' 'It is a very powerful value. Your ability to de-risk the risk is also as important for risk taking.'

USFDA raises concerns about Ranbaxy's Toansa plant

All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.

'All my stocks are crashing. Hold them?'

Ajit Mishra, vice president, research, Religare Broking, answers your queries.

Ranbaxy recalls some batches of generic Lipitor in latest quality blow

The recall is the latest in a series of problems to hit Ranbaxy, which has had all its India factories stopped from sending drugs and ingredients to the United States.

FDA finds contaminated drug ingredient at GSK Ireland plant

The FDA has stepped up its efforts to ensure drug safety in recent months.

'Advisable to invest in markets now?'

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Markets slip ahead of key eco data, rupee weighs

Markets extended losses to end 1.5% down on Tuesday, amid weak global cues, after investors turned cautious ahead of key economic data and booked profits in rate sensitive shares while the further fall in the rupee continued to weigh on investor sent.

Drugmakers draw more FDA scrutiny as US imports rise

And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.

Suspected human hair in tablet cited in Ranbaxy ban

Ranbaxy, which is 63.5 per cent-owned by Japan's Daiichi Sankyo Co and gets more than 40 per cent of its sales from the United States, did not immediately respond to a request on Wednesday for comment on the FDA observations.

Making losses in stocks? Here's help

Ajit Mishra, vice president, Research, Religare Broking, answers your queries

Confused about the stock market? Here's Help

'Is it advisable to have more number of scrips in small quantities or a few scrips in big quantities?'

India acts to repair reputation as drugs exporter

As part of the charm offensive, New Delhi has invited global regulators -- including the FDA -- to visit Indian production units to get first-hand evidence of measures taken to ensure the quality of locally manufactured generics.

India's drug inspectors hard-pressed to scrutinise factories

There are just 1,500 drug inspectors responsible for more than 10,000 factories in India

Ratan Tata, Ramadorai in new TCS board

Insulin firms see price cuts by MNCs as pressure t

Sun Pharma unit recalls mutiple lots of capsules from US

The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.

Should you accumulate this stock for 15-20 years?

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Stock advice: Buy, sell, hold or avoid?

Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis

Stock advice: Readers' queries answered!

Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis

Stocks you must buy, hold or exit in the New Year

Ajit Mishra, Vice President, Research, Religare Broking, answers readers's queries on stocks they own or want to buy.

US Fed rate hike boosts Sensex by 309 points; Nifty ends near 7,850

Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.

Sensex tumbles 261 points, Nifty near 4-month low

The 30-share Sensex ended down 261 points at 27,177 and the 50-share Nifty ended down 91 points at 8,214.

Pharma in 2014: Deals worth billions and fines worth millions

In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.